VivoSeq
Other

Envafolimab

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Envafolimab is an early-stage landscape with 0 programs across 1 company. The most active players are 3D Medicines (Sichuan) Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

3

3D Medicines (Sichuan) Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
Completed·ZZhejiang University·Phase 2·NCT05213221·39 enrolled
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Recruiting·—·Phase 2·NCT06321081·60 enrolled
Phase I Trial of Envafolimab for Healthy Male Subjects
Completed·33D Medicines (Sichuan) Co., Ltd.·Phase 1·NCT05849311·160 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)